Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 58, showing 10 Applications out of 576 total, starting on record 71, ending on 80

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

71.

ECCT/25/02/03   NOZE20240219TB
    “Validation of a Digital Olfaction Based Breathalyzer Device for Non-Invasive Detection of Volatile Biomarkers in Patients with and without Tuberculosis: Case Control Study”.   
Principal Investigator(s)
1. Ibrahim Daud
Site(s) in Kenya
KEMRI/WRP CRC Kericho
 
15-05-2025 View

72.

ECCT/24/11/01   Sparkle
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Site 1401:Victoria Biomedical Research Institute (Kisumu county)
2. Site 1402:Ahero Clinical trials Unit (Kisumu county)
3. Site 1403:International Cancer institute (Uasin Gishu county)
4. Site 1404:Kondele Childrens Hospital (Kisumu county)
5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county)
6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county)
 
13-05-2025 View

73.

ECCT/25/01/03   FETAL LITE STUDY
    Evaluation of Fetal Lite Device for Reducing Perinatal Mortality through Enhanced Labor Monitoring in Low-Resource Settings: A Pilot Study at Kenyatta National Hospital   
Principal Investigator(s)
1. GEORGE GWAKO
2. Alfred Osoti
3. Rosa Chemwey
Site(s) in Kenya
Kenyatta National Hospital
 
13-05-2025 View

74.

ECCT/24/12/03   PrEMIA Implementation study
    Multi-product PrEP delivery to young women seeking reproductive health services and coverage of HIV prevention   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD( (THIKA) PROJECT
 
04-05-2025 View

75.

ECCT/24/10/04   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Aga Khan University Hospital Nairobi (Nairobi City county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
30-04-2025 View

76.

ECCT/25/04/07   Server migration
    Server Migration   
Principal Investigator(s)
1. Server Migration Server Migration
Site(s) in Kenya
Server Migration
 
30-04-2025 View

77.

ECCT/24/10/05   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
29-04-2025 View

78.

ECCT/25/02/02   HPV vaccine feasibility study
    Generating local data on HPV vaccination impact and training needs at the level of vaccine implementers – A feasibility study   
Principal Investigator(s)
1. Prof Kenneth Ngure
Site(s) in Kenya
KEMRI-CCR PHRD( (THIKA) PROJECT
 
29-04-2025 View

79.

ECCT/25/01/01   FLORAL
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Bernhard Ogutu
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
2. Gertrude’s Children’s Hospital (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
 
24-04-2025 View

80.

ECCT/24/07/02   TMC278LAHTX4002
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county)
 
16-04-2025 View